Press Release History - 2012

  • 30 Nov 2012
    NYSE LIFFE Lists Equity Options on Thrombogenics
  • 29 Nov 2012
    ThromboGenics Lands Licensing Deal of the Year at SCRIP Awards 2012
  • 29 Nov 2012
    ThromboGenics’ Shares to Join the STOXX600 Index
  • 27 Nov 2012
    JETREA® Selected for Single Technology Appraisal (STA) by the UK’s National Institute for Health and Clinical Excellence (NICE)
  • 8 Nov 2012
    ThromboGenics Announces Business Update Q3
  • 7 Nov 2012
    ThromboGenics increases share capital through warrant exercises
  • 18 Oct 2012
    U.S. FDA Approves ThromboGenics’ JETREA® (Ocriplasmin) for the Treatment of Symptomatic Vitreomacular Adhesion (VMA).
  • 30 Aug 2012
    ThromboGenics announces business update and its financial results for the six-month period ending June 30, 2012
  • 15 Aug 2012
    ThromboGenics Announces Publication of New England Journal of Medicine Paper Entitled “Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Hole"
  • 27 Jul 2012
    FDA Advisory Committee Recommends ThromboGenics’ Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (VMA)
  • 12 Jul 2012
    ThromboGenics – Transparency Declaration
  • 3 Jul 2012
    ThromboGenics Announces FDA Accepts Filing and Grants Priority Review to Its Biologics License Application for Ocriplasmin Intravitreal Injection
  • 22 Jun 2012
    ThromboGenics to Benefit from Positive Ruling Regarding Patent Income Deduction
  • 7 Jun 2012
    ThromboGenics Receives Notice from FDA of Advisory Committee Meeting for Ocriplasmin
  • 5 Jun 2012
    ThromboGenics and BioInvent Announce Results from Phase IIb Venous Thromboembolism Prevention Study with TB-402
  • 5 Jun 2012
    ThromboGenics and BioInvent To Regain Full Rights to TB-403
  • 23 May 2012
    ThromboGenics Increases Share Capital Through Warrant Exercises
  • 10 May 2012
    ThromboGenics Announces Business Update Q1
  • 17 Apr 2012
    ThromboGenics Resubmits BLA for Ocriplasmin with the FDA
  • 13 Apr 2012
    ThromboGenics – Transparency Declaration
  • 3 Apr 2012
    ThromboGenics has in total 35,691,432 shares outstanding
  • 8 Mar 2012
    ThromboGenics Announces Business Update and 2011 Full-Year Results
  • 5 Mar 2012
    ThromboGenics Opens New U.S. Headquarters
  • 24 Feb 2012
    ThromboGenics to Present at the Citi 2012 Global Health Care Conference in New York
  • 2 Feb 2012
    ThromboGenics Announces that the FDA Intends to Grant Ocriplasmin Priority Review
  • 5 Jan 2012
    ThromboGenics Publishes Financial Calendar 2012